Arcturus Therapeutics Holdings vs Tonix Pharmaceuticals Holding
Arcturus Therapeutics Holdings is the larger business, with $82.0m of revenue in fiscal 2025 against $13.1m for Tonix Pharmaceuticals Holding (6.3 times as much). Tonix Pharmaceuticals Holding grew faster (29.8% against -46.1%). Arcturus Therapeutics Holdings kept more of each dollar of sales as profit: a net margin of -80.2% against -946.2%.
| Latest fiscal year | Arcturus Therapeutics HoldingsARCT, 2025 | Tonix Pharmaceuticals HoldingTNXP, 2025 |
|---|---|---|
| Revenue | $82.0m | $13.1m |
| Revenue growth | -46.1% | 29.8% |
| Net income | −$65.8m | −$124m |
| Operating margin | -93.0% | — |
| Net margin | -80.2% | -946.2% |
| Return on equity | -28.9% | -64.5% |
| Free cash flow | −$74.5m | −$103m |
| Cash | $231m | $208m |
| Total debt | — | — |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $13.8m |
| Employees | 111 | 142 |
| Market value | $268m | $86.9m |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 7 buys, 0 sales |